← Stock Trading Canary · All insider profiles
INSIDER PROFILE · DE
Andreas Eckert
Supervisory Board Member (Aufsichtsrat b) Berichtigung Die Käuferin der Aktien wurde falsch benannt.) | Supervisory Board Member (Aufsichtsrat) · Initial notification
Profile key: de|andreas eckert
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 3
- Purchases · 24M
- 5
- Average purchase
- —
- Gross purchase value
- —
- Last purchase
- 2026-07-30
- Completed 20D events
- 6.0
- Outcome status
- PASS
Latest company: Pentixapharm Holding AG
Companies: Pentixapharm Holding AG
Post-purchase outcomes
Benchmark-relative outcomes are available against DAX.
- Excess return = stock return − DAX return over the same period.
- Hit rate = positive excess-return events ÷ completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 6Developing | 100.0% (6/6) | 66.7% (4/6) | +0.7% | +4.0% | -0.7% |
| 20D | 6Developing | 100.0% (6/6) | 50.0% (3/6) | +0.9% | +0.1% | -5.5% |
| 60D | 5Developing | 100.0% (5/5) | 40.0% (2/5) | -13.8% | +2.1% | -23.7% |
| 120D | 5Developing | 100.0% (5/5) | 100.0% (5/5) | +17.8% | +25.6% | +5.4% |
Research patterns
- First purchase in 12M
- 0/6
- Large purchase ≥ €100k
- 0/5
- Cluster buying · 15D
- 0/6
- Buying the dip · ≥20% below prior 52W high
- 6/6
- Routine / opportunistic
- Not classifiable
Counts are profile-wide, point-in-time research labels. They never affect the insider score or ranking.
Every completed outcome is shown; n<5 is descriptive small-sample evidence and is not scored. Disclosure-level observations published on the same date may share a return path and may not be statistically independent. These results never affect the insider score or ranking.